Azenta (AZTA) Projected to Post Earnings on Tuesday

Key Points

• Azenta (NASDAQ:AZTA) is expected to report its Q3 2025 earnings on August 5th, anticipating earnings of $0.13 per share and revenue of $149.64 million.
• The company's previous quarter results showed an earnings miss, reporting $0.05 EPS compared to the expected $0.09, with a negative net margin of 10.31%.
• Analysts have mixed views, with Evercore ISI raising its price target to $35.00 while Needham & Company reduced theirs to $40.00, reflecting varying outlooks on the stock's performance.

Azenta (NASDAQ:AZTA - Get Free Report) is projected to release its Q3 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Azenta to post earnings of $0.13 per share and revenue of $149.64 million for the quarter.

Azenta (NASDAQ:AZTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.04). Azenta had a negative net margin of 10.31% and a positive return on equity of 1.30%. The firm's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS. On average, analysts expect Azenta to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Azenta Stock Down 0.7%

Azenta stock traded down $0.23 during mid-day trading on Friday, reaching $32.48. 233,629 shares of the company's stock traded hands, compared to its average volume of 761,509. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -23.41 and a beta of 1.64. The stock has a 50 day moving average of $30.81 and a two-hundred day moving average of $35.43. Azenta has a 12-month low of $23.91 and a 12-month high of $60.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new stake in Azenta in the first quarter worth about $435,000. Millennium Management LLC lifted its stake in Azenta by 214.8% in the first quarter. Millennium Management LLC now owns 340,580 shares of the company's stock worth $11,798,000 after acquiring an additional 232,405 shares during the period. Empowered Funds LLC lifted its stake in Azenta by 10.5% in the first quarter. Empowered Funds LLC now owns 6,482 shares of the company's stock worth $225,000 after acquiring an additional 618 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Azenta by 17.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company's stock worth $6,974,000 after acquiring an additional 30,492 shares during the period. 99.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AZTA. Stephens began coverage on shares of Azenta in a research report on Tuesday, July 22nd. They set an "equal weight" rating and a $35.00 price objective on the stock. Evercore ISI boosted their price objective on shares of Azenta from $29.00 to $35.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Finally, Needham & Company LLC cut their price objective on shares of Azenta from $59.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.